Table 2.
Therapy response to MCT and its prior and subsequent therapy
| Therapy | MCT overall | CTX/MTX | CTX/CAPE | CTX | VRL | Therapy prior to MCT | Therapy subsequent to MCT |
|---|---|---|---|---|---|---|---|
| Patients, n (%) | 72 | 62 (86.1) | 3 (4.2) | 2 (2.8) | 5 (6.9) | 67 | 46 |
| DCR ≥24 weeks, n (%) | 23 (31.9) | 19 (30.6) | 1 (33.3) | 1 (50.0) | 2 (40.0) | 22 (32.8) | 8 (17.4) |
| p value | 0.919 | 0.570 | 0.038 | ||||
| SD/PR/CR (≥24 weeks), n (%) | 15 (20.8)/7 (9.7)/1 (1.4) | 11 (17.7)/7 (11.3)/1 (1.6) | 1 (33.31/0 (0.0)/0 (0.0) | 1 (50.01/0 (0.0)/0 (0.0) | 2 (40.01/0 (0.0)/0 (0.0) | 14 (20.9)/8 (11.9)/0 (0.0) | 8 (17.4)/0 (0.0)/0 (0.0) |
| p value | 0.932 | 0.763 | 0.001 | ||||
| PFS (weeks) (median, 95% CI) | 17.0 (14.5-19.5) | 17.0 (13.9-20.1) | 17.0 (9.0-25.0) | 4.0 (N/A) | 17.0 (15.9-18.1) | 20.0 (16.6-23.4) | 12.0 (9.1-14.9) |
| p value | 0.410 | 0.093 | 0.006 | ||||
| OS (weeks) (median, 95% CI) | 58.0 (29.0-87.0) | 47.0 (25.7-68.3) | 138.0 (N/A) | 4.0 (N/A) | 160.0 (112.8-207.2) | N/A | N/A |
| p value | 0.127 | N/A | N/A |
CTX, cyclophosphamide; MTX, methotrexate; CAPE, capecitabine; VRL, vinorelbine; DCR, disease control rate; SD, stable disease; PR, partial response; CR, complete response; CI, confidence interval; PFS, progression-free survival; OS, overall survival.